TRANSFORM-HF Ancillary Mechanistic Study

Inova Health Care Services

Status: Completed

Conditions: Heart Failure

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT04702958

R01HL154768-01 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Patients with heart failure are frequently treated with diuretics, including furosemide and torsemide, but it is not known if one is better than the other. The TRANSFORM-HF trial is studying if torsemide is superior than furosemide for reducing the endpoint of death or hospitalization, but is not designed to study why. This ancillary study seeks to measure proteins in the blood and urine to help explain the underlying mechanism for why patients who take one of these diuretics may have better outcomes than patients who take the other.

Full description

Patients who are enrolling in the TRANSFORM-HF study or being prescribed Torsemide or Furosemide at hospital discharge will provide blood and urine at the time of study enrollment (within 72 hours of hospital discharge) and at 90 days (+/- one week) after hospital discharge.

Enrollment: 150 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participation in the TRANSFORM-HF trial or prescription of Torsemide or Furosemide
• Willing to provide blood and urine sample at enrollment and follow-up

Exclusion criteria

• Inability or unwillingness to comply with the study requirements

Trial design

150 participants in 2 patient groups

Torsemide

Description:

Patients enrolled in the TRANSFORM-HF study randomized to Torsemide, or patients prescribed Torsemide at hospital discharge

Furosemide

Description:

Patients enrolled in the TRANSFORM-HF study randomized to Furosemide, or patients prescribed Furosemide at hospital discharge